

September 6, 2013

Dear Colleague,

Orphan diseases, for which there are no cures, can have deleterious effects on the body, mind and spirit. Perhaps, the hardest challenge of all is when patients have no hope for the future and have relentless symptoms that compromise quality of life. Unfortunately, many patients with pheochromocytoma and paraganglioma are subject to such feelings and conditions.

The Pheochromocytoma Research Support Organization (PRESSOR) is a non-profit consortium of health science professionals at medical and academic institutions around the world who are committed to changing this paradigm. Basic scientists and clinicians who are separated by miles but united by their resolve have joined forces to effect major advances in the lab and through translational research.

PRESSOR was created to provide the organizational framework that is necessary to make significant strides in treating and finding a cure for these diseases. Bringing together the brightest minds in this field provides new insights and therapies that would otherwise be difficult to achieve. When patient cohorts are small and resources are limited, it takes a cohesive, committed group of specialists to overcome these challenges – and we are doing that!

We are proud of PRESSOR's growth and success since its creation in 2003. Over this relatively short period of time, PRESSOR has organized three international Symposia on research and treatment of pheochromocytomas and paragangliomas in Washington, D. C., Cambridge, United Kingdom, and Paris, France. As a result of these meetings, professional collaborations developed, resulting in significant progress in the diagnosis and treatment of these tumors. We are very excited to announce that the 4th International Symposium on Pheochromocytoma and Paraganglioma research will be held in Kyoto, Japan, in September 14-17, 2014.


PRESSOR will soon have an updated webpage and a new directory. *We kindly request our current members to update and resubmit their information in the PRESSOR directory. We also encourage all interested investigators and clinicians to submit their information at no cost.* When you join forces with PRESSOR you are not just joining another organization... You will be helping to give patients with pheochromocytoma and paraganglioma a reason to be hopeful.

Please go to www.pressor.org to subscribe to PRESSOR. Welcome on board!

Sincerely,



Mercedes Robledo, PhD
Centro Nacional de Investigaciones
Oncologicas
Madrid, Spain



Camilo Jimenez, MD
Associate Professor
Department of Endocrine Neoplasia and Hormonal
Disorders
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA